Ken serves as the Founding General Partner of CTI LFS, with a distinguished tenure of over 20 years with the firm. Throughout his extensive career, he has overseen all the investments made by CTI. Ken was responsible for building GLyPharma, one of CTI's most important success stories. GLyPharma transacted in equity with Theracon, which Pfizer purchased. Ken subsequently took the original GLyPharma asset and established VectivBio, which Ironwood recently purchased for >$1B. He was also responsible for many of CTI’s key transactions.

Ken brings over 30 years of financial experience in private and public equity as a portfolio manager and investment banker. Currently, Mr. Pastor serves as a Board Member and Chair of the Audit Committee of the Quebec Consortium for Drug Discovery (CQDM), a partnership between academic hospitals, pharmaceutical companies, and the biotechnology industries in the private sector. Ken has a Master’s degree in economics from the University of Montreal. He is also a CVCA, Reseau Capital, and BioQuebec member.

‍